75 related articles for article (PubMed ID: 2143128)
1. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
2. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.
Garam N; Prohászka Z; Szilágyi Á; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik-Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Romana Rysava ; Reiterova J; Saraga M; Tomáš Seeman ; Zieg J; Sládková E; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Csuka D
Orphanet J Rare Dis; 2019 Nov; 14(1):247. PubMed ID: 31703608
[TBL] [Abstract][Full Text] [Related]
3. Causes of alternative pathway dysregulation in dense deposit disease.
Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
[TBL] [Abstract][Full Text] [Related]
4. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH
Front Immunol; 2022; 13():1073802. PubMed ID: 36846022
[TBL] [Abstract][Full Text] [Related]
5. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.
Ravindran A; Fervenza FC; Smith RJH; De Vriese AS; Sethi S
Mayo Clin Proc; 2018 Aug; 93(8):991-1008. PubMed ID: 30077216
[TBL] [Abstract][Full Text] [Related]
6. C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor.
Anderson H; Van Voorthuizen M; O'Donnell J; Beck S
J Clin Pathol; 2024 Mar; ():. PubMed ID: 38538072
[TBL] [Abstract][Full Text] [Related]
7. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.
Rose KL; Paixao-Cavalcante D; Fish J; Manderson AP; Malik TH; Bygrave AE; Lin T; Sacks SH; Walport MJ; Cook HT; Botto M; Pickering MC
J Clin Invest; 2008 Feb; 118(2):608-18. PubMed ID: 18202746
[TBL] [Abstract][Full Text] [Related]
8. Circulating complement levels and C3 glomerulopathy.
Fervenza FC; Sethi S
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1829-31. PubMed ID: 25341723
[No Abstract] [Full Text] [Related]
9. A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins.
Garcia BL; Summers BJ; Ramyar KX; Tzekou A; Lin Z; Ricklin D; Lambris JD; Laity JH; Geisbrecht BV
J Biol Chem; 2013 Jan; 288(4):2870-81. PubMed ID: 23233676
[TBL] [Abstract][Full Text] [Related]
10. A healthy female with C3 hypocomplementemia and C3 Nephritic Factor.
Egan M; Sullivan K; Frazer-Abel A; Cunningham-Rundles C
Clin Immunol; 2016 Aug; 169():14-15. PubMed ID: 27263803
[No Abstract] [Full Text] [Related]
11. Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy.
Hauer JJ; Zhang Y; Goodfellow R; Taylor A; Meyer NC; Roberts S; Shao D; Fergus L; Borsa NG; Hall M; Nester CM; Smith RJH
Kidney Int Rep; 2024 Feb; 9(2):464-477. PubMed ID: 38344720
[TBL] [Abstract][Full Text] [Related]
12. A Monoclonal Antibody That Provides a Model for C3 Nephritic Factors.
Hourcade DE; Mitchell LM
Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):9-14. PubMed ID: 36853837
[TBL] [Abstract][Full Text] [Related]
13. Challenges in diagnostic testing of nephritic factors.
Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
Front Immunol; 2022; 13():1036136. PubMed ID: 36451820
[TBL] [Abstract][Full Text] [Related]
14. Physiology and pathology of the C3 amplification cycle: A retrospective.
Peters K
Immunol Rev; 2023 Jan; 313(1):217-224. PubMed ID: 36408746
[TBL] [Abstract][Full Text] [Related]
15. Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.
Radanova M; Mihaylova G; Ivanova D; Daugan M; Lazarov V; Roumenina L; Vasilev V
Clin Exp Immunol; 2020 Aug; 201(2):135-144. PubMed ID: 32306375
[TBL] [Abstract][Full Text] [Related]
16. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP; Esposito P; Rossini M
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947692
[TBL] [Abstract][Full Text] [Related]
17. The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.
Defendi F; Thielens NM; Clavarino G; Cesbron JY; Dumestre-Pérard C
Clin Rev Allergy Immunol; 2020 Apr; 58(2):229-251. PubMed ID: 31834594
[TBL] [Abstract][Full Text] [Related]
18. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
19. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
Zhao F; Afonso S; Lindner S; Hartmann A; Löschmann I; Nilsson B; Ekdahl KN; Weber LT; Habbig S; Schalk G; Kirschfink M; Zipfel PF; Skerka C
Front Immunol; 2019; 10():1030. PubMed ID: 31214159
[TBL] [Abstract][Full Text] [Related]
20. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
Front Immunol; 2019; 10():886. PubMed ID: 31068950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
